upsid quarter margin fall bit short
currenc cc vs guid our/street estimate
upsid driven strength core breast health diagnost busi
improv surgic perform strong ou growth well better expect
blood screen organ basi ex blood sale increas yoy
ad gm declin yoy estimate chiefli
due neg impact non-recur factor unfavor product mix
opm also declin yoy vs estim ep vs
our/street est grew yoy due part better cost control
cyno write-down guid rais core trend strong
management updat guid yoy cc revenu growth
previou rang recent acquisit
faxitron focal contribut quarter expect
impli yoy pro forma organ revenu growth
ep guid rais account cost save
ep also line our/street est overal
good quarter nearli core growth molecular diagnost mdx core
growth breast imag ou growth comp get tougher
updat guid suggest ep upsid may limit final cynosur cyno continu
fall short took impair charg quarter
write-down management see low mid-singl digit declin
instead return growth forecast declin previous
rais sale ep estimate
post result updat guid reiter neutral rate po
base ep estimate ahead histor averag
in-lin diagnost peer
full definit iqmethod sm measur see page
net dbt
bofa merril lynch seek busi issuer cover research report
result investor awar firm may conflict interest could
affect object report investor consid report singl
factor make invest decis
refer import disclosur page analyst certif page price object
basis/risk page
return capit employ
return equiti
iqmethod sm qualiti earn
net incom cont oper
chang work capit
full definit iqmethod sm measur see page
lead manufactur medic
devic product focus heathcar need
mammographi breast biopsi earli stage
treatment remov uterin fibroid
compani acquir cynosur lead
medic aesthet compani larg portfolio
laser-bas product
core mammographi diagnost
busi deliv solid perform
especi ou market help
partial off-set issu relat
cynosur busi acquir continu
reserv cynosur
lack visibl concern although
po base approxim calendar ep estim impli
ev/ebitda ahead three-year histor averag in-
line compani diagnost med-tech peer multipl believ
justifi given strength breast molecular diagnost
upsid risk po better-than-expect synergi cynosur
acquisit unreal benefit chang tax code faster growth
core diagnost mammographi gynecolog surgeri end market
downsid risk po cynosur competit pressur slower uptak
reimburs new product unfavor chang clinic practic guidelin
manag departur regulatori risk faster declin legaci busi
derik de bruin herebi certifi view express research report
accur reflect person view subject secur issuer also
certifi part compens directli indirectli relat
specif recommend view express research report
us life scienc diagnost tool anim health coverag cluster
qualiti earn
iqmethod smi set bofa merril lynch standard measur serv maintain global consist three broad head busi perform qualiti earn valid key featur
iqmethod consist structur detail transpar methodolog guidelin maxim effect compar valuat process identifi common pitfal
iqdatabas real-tim global research databas sourc directli equiti analyst earn model includ forecast well histor data incom statement balanc sheet cash
flow statement compani cover bofa merril lynch
iqprofil sm iqmethod sm servic mark america corpor iqdatabas regist servic mark america corpor
